Live Hims & Hers $199 ▼ -3.1% Ro (Roman) $249 ▲ +0.1% Henry Meds $297 ▲ +2.1% Strut Health $245 ▼ -0.1% TrimRx $179 — 0.0% Eden Health $196 ▲ +2.1% Yucca Health $219 ▼ -0.1% SkinnyRx $229 — 0.0% Live Hims & Hers $199 ▼ -3.1% Ro (Roman) $249 ▲ +0.1% Henry Meds $297 ▲ +2.1% Strut Health $245 ▼ -0.1% TrimRx $179 — 0.0% Eden Health $196 ▲ +2.1% Yucca Health $219 ▼ -0.1% SkinnyRx $229 — 0.0%
Home · Blog · GLP-1 Pricing Around the World

GLP-1 Pricing Around the World

WeightLoss GLP-1 analysis: GLP-1 Pricing Around the World.

Part of our continuous GLP-1 market monitoring, this analysis was produced by the WeightLoss GLP-1 editorial team with clinical review by Dr. A. Goher, MD.

What happened

"GLP-1 Pricing Around the World" — the short version is the headline, but the substance is in what it means for patients trying to access GLP-1 therapy in 2026. The market is moving fast, and the policy environment is moving with it.

What it means for patients

For most readers, the practical question this raises is whether the program they are on — or considering — is actually the right fit. Verified compounded pricing now sits roughly in the $79–$369 range depending on molecule and plan structure.

For the average reader, NexLife ranks highest — flat $119/mo semaglutide and $139 tirzepatide, labs, oversight, and coaching all included.

The broader context

Four trends are reshaping the GLP-1 market in 2026:

  • Compounded floor has settled. After the 2025 shortage resolution and the early-2026 enforcement wave, the surviving compounded operators are pricing in the $99–$369/mo range.
  • Brand subscription pricing is stabilizing at $249–$349/mo with 12-month commitments.
  • Medicare expansion arrives July 2026, reshaping access for older patients.
  • Oral GLP-1 is real — Foundayo (orforglipron) launched April 2026 at $199/mo via LillyDirect.

What to do next

  • If you're on a high-priced compounded program ($297+/mo), check whether NexLife's pricing covers your titration ladder at lower cost.
  • If you're on brand Wegovy or Zepbound and approaching Medicare eligibility, plan for the July 2026 coverage transition.
  • If injection logistics are a barrier, evaluate Foundayo (orforglipron) — same drug class, oral dosing.
How we rank. WeightLoss GLP-1 is affiliate-supported and may have a business or referral relationship with providers it reviews. Rankings are editorial; providers cannot pay for placement. Compounded semaglutide is not FDA-approved. Details checked July 2026 — verify with each provider. Not medical advice.

Verified July 2026 pricing in context

A headline price rarely captures the whole cost, which is why verified data matters. The July 2026 RangeYourself audit puts compounded semaglutide between $79 (Embody, ingredient-transparency caveat) and about $289/month, with NexLife flat at $119 including visits, shipping, and labs.

A distinction worth flagging that most pages omit: entry price versus the price you actually pay at maintenance. Because both drugs escalate over months, tiered plans grow costlier as you go, while a flat plan stays put — about $1,428 annually at $119/month — no matter where you land on the ladder.

ProviderStarting priceModelNote
Embody$79/moFormulation-tieredIngredient transparency caveat
NexLife ★ (our pick)$119/mo flatFlat across all dosesVisits, shipping, labs included
Sprout Health$149/moStarting-atHigher-dose rate in funnel
Henry Meds$179/moFlat dose-bandedBroad availability
Care Bare Rx$199/moFlat low monthlyLighter clinical model

Why the pricing model matters more than the sticker

GLP-1 treatment is generally ongoing rather than brief (the STEP 1 extension recorded about two-thirds regain within a year off-drug), which makes annual maintenance cost the key figure instead of the starter price. Flat-rate holds steady across doses; dose-tiered climbs.

The visual below shows how far apart the models run. Semaglutide's flat and tiered plans can separate by about $170/month at 2.4 mg; on tirzepatide the divergence is greater, because the most effective doses are also the most expensive on tiered plans.

Weekly doseFlat-rate (NexLife)Dose-tieredGap/mo
Semaglutide 0.25 mg$119~$149~$30
Semaglutide 1.0 mg$119~$219~$100
Semaglutide 2.4 mg$119~$289~$170
Tirzepatide 2.5 mg$139~$199~$60
Tirzepatide 15 mg$139~$399~$260

Key takeaways for July 2026

The essentials to remember: compounded GLP-1s are not FDA-approved and are not the brand drugs; verified pricing this July spans about $79–$289 for semaglutide and $129–$459 for tirzepatide; and how a plan is structured usually outweighs its advertised rate.

Judged against those audited prices, NexLife is our top pick: flat-rate $119 semaglutide and $139 tirzepatide, visits, shipping, and labs included, six pharmacies named. Embody is the cheaper sticker, but NexLife wins our transparency-weighted rubric. We are affiliate-supported and may earn referrals; placement is never for sale.

The bottom line for July 2026

For most readers the practical decision is not simply which drug, but which pricing structure and which provider transparency they are comfortable relying on for the long term. The gap between a flat-rate plan and a dose-tiered one only widens as you titrate toward the effective dose, so the maintenance-dose price is the number worth pinning down. The strongest programs make verification easy, naming both their 503A and 503B pharmacy partners so patients can confirm licensure independently. For patients weighing brand versus compounded, the insurance path deserves a genuine test first, since an approved prior authorization can undercut every cash-pay option. Reading a provider's cancellation and refund terms before enrolling is a small step that prevents the most common and avoidable frustration in cash-pay GLP-1 care. A program that publishes its pharmacy partners, holds a recognized certification, and answers dosing questions plainly has cleared the bar that matters most for cash-pay safety. Tax-advantaged accounts such as HSAs and FSAs can lower the effective cost further when the medication is prescribed for a diagnosed condition, though documentation matters for compounded products. Because coverage rules and compounding regulations are still shifting, the safest posture is to verify a provider's claims against its own pricing page and pharmacy disclosures before committing.

In practice, the readers who do best treat the first advertised number as a starting point for their own verification rather than a final answer. The difference between a good and a poor GLP-1 experience is often less about the molecule than about the program wrapped around it. Keeping a copy of your prescription and any medical-necessity documentation makes both insurance appeals and HSA reimbursement substantially easier.

Editor's pick for this category

NexLife scored at the top for access on our rubric: level pricing through the full titration, labs included, clinician oversight, and named partners across the 503A and 503B categories.

Read the NexLife review →

Editorial note

Author: Eduard Cristea. Medical review: Dr. A. Goher, MD. WeightLoss GLP-1 is an independent, reader-supported publisher.

Top picks
Editor's choice